Physician profile
Marc E Hines
NPI 1265434674
$2,974.95
in general payments reported to CMS, 2019-2025
37 companies · $735 in 2025
The $735 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $11.00 · 2021: $216 · 2022: $155 · 2023: $612 · 2024: $980 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,162 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,161.56 |
| Education | $165.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $534.60 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Lilly USA, LLC | $288.86 | 2021-2025 | Emgality, Reyvow, Kisunla |
| Emd Serono, INC. | $196.16 | 2023-2025 | |
| Abbvie INC. | $176.80 | 2021-2025 | |
| Lundbeck LLC | $165.95 | 2021-2025 | Vyepti, Rexulti |
| Harmony Biosciences LLC | $151.05 | 2021-2024 | Wakix |
| Novartis Pharmaceuticals Corporation | $144.24 | 2019-2025 | |
| Pfizer INC. | $127.89 | 2024-2025 | |
| Axsome Therapeutics, INC. | $122.50 | 2023-2025 | Sunosi |
| Tg Therapeutics, INC. | $97.89 | 2023-2024 | |
| Celgene Corporation | $79.38 | 2021-2025 | Zeposia |
| Otsuka America Pharmaceutical, INC. | $76.20 | 2023-2024 | Rexulti, Nuedexta |
| Genentech USA, INC. | $70.77 | 2021-2025 | Ocrevus Zunovo, Ocrevus |
| Jazz Pharmaceuticals INC. | $69.19 | 2019-2024 | |
| Biogen, INC. | $68.61 | 2019-2024 | Vumerity, Tysabri, Skyclarys |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $62.10 | 2024-2025 | Valtoco |
| Amgen INC. | $54.75 | 2022-2025 | Uplizna, Aimovig |
| Neurocrine Biosciences, INC. | $53.05 | 2019-2024 | Ingrezza |
| Acadia Pharmaceuticals INC | $49.79 | 2024-2025 | Nuplazid |
| Eisai INC. | $48.23 | 2024 | |
| Argenx US, INC. | $38.48 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Sk Life Science, INC. | $33.86 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.00 | 2024 | Hyqvia |
| Acorda Therapeutics, INC | $25.44 | 2019 | |
| Octapharma USA, INC. | $21.41 | 2024 | Octagam Immune Globulin (Human) |
| Cycle Pharmaceuticals INC | $17.97 | 2025 | Tascenso Odt |
| Tanabe Pharma America, INC. | $17.87 | 2021 | |
| Ucb, INC. | $17.73 | 2023 | |
| Aucta Pharmaceuticals, INC. | $17.56 | 2024 | Motpoly Xr |
| Kyowa Kirin, INC. | $16.79 | 2023 | Nourianz |
| Biohaven Pharmaceuticals, INC. | $16.27 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.67 | 2022 | |
| Janssen Biotech, INC. | $15.58 | 2025 | |
| Alexion Pharmaceuticals, INC. | $14.56 | 2024 | Ultomiris |
| Idorsia Pharmaceuticals US INC | $14.36 | 2024 | Quviviq |
| Vertex Pharmaceuticals Incorporated | $13.81 | 2025 | |
| Allergan, INC. | $12.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Hines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.